Cholera Vaccines

Global Cholera Vaccines Market to Reach US$147.4 Million by 2030

The global market for Cholera Vaccines estimated at US$91.1 Million in the year 2024, is expected to reach US$147.4 Million by 2030, growing at a CAGR of 8.4% over the analysis period 2024-2030. Killed Oral O1 and O139 Vaccine, one of the segments analyzed in the report, is expected to record a 10.1% CAGR and reach US$86.4 Million by the end of the analysis period. Growth in the Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine segment is estimated at 6.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$24.8 Million While China is Forecast to Grow at 13.3% CAGR

The Cholera Vaccines market in the U.S. is estimated at US$24.8 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$32.4 Million by the year 2030 trailing a CAGR of 13.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.1% and 8.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.6% CAGR.

Global Cholera Vaccines Market – Key Trends & Drivers Summarized

Why Is the Demand for Cholera Vaccines Increasing?

The demand for cholera vaccines is increasing due to the rising incidence of cholera outbreaks, the growing need for preventive healthcare measures in endemic regions, and global initiatives aimed at eliminating cholera as a public health threat. Cholera remains a major concern in developing countries, particularly in areas with inadequate sanitation and limited access to clean water. As urbanization and climate change contribute to the spread of waterborne diseases, the demand for effective vaccines to prevent cholera infections has intensified. Governments, non-governmental organizations, and global health agencies such as the World Health Organization and Gavi, the Vaccine Alliance, are actively investing in large-scale cholera vaccination programs. Mass immunization efforts, emergency stockpiling of vaccines, and increased funding for vaccine development have further driven market growth. Additionally, rising travel to high-risk areas has led to an increase in the adoption of cholera vaccines among travelers, further boosting demand. As global health initiatives continue to expand, the need for cholera vaccines remains strong.

How Are Technological Advancements Improving Cholera Vaccines?

Advancements in vaccine development, production efficiency, and delivery mechanisms are significantly improving the accessibility and effectiveness of cholera vaccines. One of the most notable innovations is the development of oral cholera vaccines, which provide easier administration and broader coverage in mass immunization campaigns. These vaccines, such as those using killed whole-cell or live-attenuated strains, offer long-lasting immunity while reducing logistical challenges associated with injectable vaccines. Another major breakthrough is the implementation of recombinant DNA technology and synthetic biology in vaccine manufacturing. These innovations allow for the production of more stable, affordable, and scalable vaccines, making them accessible to low-income regions where cholera is most prevalent. Additionally, improvements in cold chain logistics and heat-stable formulations are enabling better vaccine distribution in remote areas with limited infrastructure. As vaccine technology continues to evolve, the global reach of cholera immunization programs is expected to expand, reducing the disease burden in vulnerable populations.

Which Market Trends Are Driving Growth in the Cholera Vaccines Market?

The increasing focus on preventive healthcare and epidemic preparedness is one of the key trends shaping the cholera vaccines market. Governments and international organizations are prioritizing proactive vaccination campaigns to prevent outbreaks rather than relying solely on post-epidemic treatment. This shift in approach has led to greater demand for stockpiled vaccines and preemptive immunization efforts in high-risk regions. Another significant trend influencing market growth is the expansion of public-private partnerships in vaccine research and distribution. Collaborations between pharmaceutical companies, research institutions, and global health organizations are driving innovations in cholera vaccine development and improving access to vaccines in underserved areas. Additionally, the rise of combination vaccines that protect against multiple bacterial infections, including cholera, is gaining attention as a cost-effective and efficient immunization strategy. As these trends continue to shape the market, cholera vaccines are becoming a central tool in global public health efforts.

What Are the Key Growth Drivers Shaping the Future of the Cholera Vaccines Market?

The growth of the cholera vaccines market is driven by several factors, including increasing investments in immunization programs, rising awareness of cholera prevention, and advancements in vaccine production technology. One of the primary growth drivers is the growing number of humanitarian and emergency response initiatives targeting cholera-endemic regions. Organizations involved in disaster relief and refugee health programs are incorporating cholera vaccination as a standard preventive measure, further driving demand. Another crucial factor shaping the market is the expansion of travel-related vaccine recommendations. As more people travel to cholera-prone areas for work, tourism, or humanitarian missions, the demand for pre-travel vaccination has increased. Additionally, ongoing research into next-generation cholera vaccines with improved efficacy and longer-lasting immunity is expected to drive further adoption. With continued global efforts to control and eliminate cholera, the market for vaccines is set to experience sustained growth, improving health outcomes in both endemic and high-risk regions.

SCOPE OF STUDY:

The report analyzes the Cholera Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product Type (Killed Oral O1 and O139 Vaccine, Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine); Cholera Type (Dukoral, Vaxchora, Shanchol, Other Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Astellas Pharma Inc.
• Bavarian Nordic
• Bharat Biotech Ltd.
• Celldex Therapeutics
• Emergent BioSolutions Inc.
• EuBiologics Co., Ltd.
• GlaxoSmithKline plc (GSK)
• Hilleman Laboratories
• Incepta Vaccine Ltd.
• International Vaccine Institute
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• PaxVax, Inc.
• Pfizer Inc.
• Sanofi S.A.
• Shanghai United Cell Biotechnology Co., Ltd.
• Shantha Biotechnics Limited
• Takeda Pharmaceutical Company Limited
• Vabiotech
• Valneva SE

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.